摘要: Several agents that target specific molecules have been investigated for the treatment of gastric cancer in many preclinical and clinical studies. Anti-HER2 antibody, when combined with classical cytotoxic agents, has shown to confer a significant survival benefit patients HER2-positive cancer. This is only targeted drug be successful We need determine targets regulating cells by translational research, develop precise diagnostic procedures personalized medicine, identify candidate drugs
amegroups.com参考文章(48)
Kimberly L. Blackwell, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do-Youn Oh, Veronique Dieras, Steven R. Olsen, Liang Fang, Michael W Lu, Ellie Guardino, Sunil Verma, Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Journal of Clinical Oncology. ,vol. 30, pp. LBA1- LBA1 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA1
Tomislav Dragovich, Christopher Campen, Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology. ,vol. 2009, pp. 804108- 804108 ,(2009) , 10.1155/2009/804108
Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, Yousuke Tamura, Hiroshi Nokihara, Yasuhide Yamada, Tomohide Tamura, Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors Cancer Chemotherapy and Pharmacology. ,vol. 73, pp. 511- 516 ,(2014) , 10.1007/S00280-014-2375-2
Taroh Satoh, Yasuhide Yamada, Kei Muro, Hidetoshi Hayashi, Yasuhiro Shimada, Daisuke Takahari, Keisei Taku, Takako Eguchi Nakajima, Xiaojin Shi, Kathryn H. Brown, Narikazu Boku, Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 439- 446 ,(2012) , 10.1007/S00280-011-1723-8
Yoshinori Hirashima, Yasuhide Yamada, Junichi Matsubara, Daisuke Takahari, Natsuko Okita, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Kuniaki Shirao, Yasuhiro Shimada, Hirokazu Taniguchi, Tadakazu Shimoda, Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Science. ,vol. 100, pp. 310- 315 ,(2009) , 10.1111/J.1349-7006.2008.01020.X
M. Moehler, A. Mueller, J.T. Hartmann, M.P. Ebert, S.E. Al-Batran, P. Reimer, M. Weihrauch, F. Lordick, T. Trarbach, S. Biesterfeld, M. Kabisch, D. Wachtlin, P.R. Galle, An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. European Journal of Cancer. ,vol. 47, pp. 1511- 1520 ,(2011) , 10.1016/J.EJCA.2011.04.006
Xiu Li Zhang, Yun Sheng Yang, Dong Ping Xu, Jian Hui Qu, Ming Zhou Guo, Yan Gong, Jin Huang, Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World Journal of Surgery. ,vol. 33, pp. 2112- 2118 ,(2009) , 10.1007/S00268-009-0142-Z
Takashi Ichikura, Soichi Tomimatsu, Eiji Ohkura, Hidetaka Mochizuki, Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma Journal of Surgical Oncology. ,vol. 78, pp. 132- 137 ,(2001) , 10.1002/JSO.1133
Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero, Phase II study of sunitinib as second-line treatment for advanced gastric cancer Investigational New Drugs. ,vol. 29, pp. 1449- 1458 ,(2011) , 10.1007/S10637-010-9438-Y
Young-Kwang Yoon, Seock-Ah Im, Ahrum Min, Hwang-Phill Kim, Hyung-Seok Hur, Kyung-Hun Lee, Sae-Won Han, Sang-Hyun Song, Do Youn Oh, Tae-You Kim, Woo Ho Kim, Yung-Jue Bang, Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Letters. ,vol. 321, pp. 128- 136 ,(2012) , 10.1016/J.CANLET.2012.01.019